GPR35; DRD4; GPBAR1; | |
NPSR1; CXCR1; | |
AMY1A;AMY1B;AMY1C; PLA2G1B; TDP1; BLM; APOBEC3G; FAAH; RECQL; TERT; PIK3CG; PIK3R1; GLO1; HPGD; HSD11B1; MPO; HSD17B1; AKR1B1; HSD17B10; ALOX15; ALDH1A1; AKR1B10; HSD17B2; ALOX12; GFER; NOX4; USP2; TNKS; PARP1; TNKS2; PYGL; APEX1; POLB; CD38; | |
PTPRF; PTPN1; CDC25B; DUSP3; PTPN2; ACP1; | |
ACHE; GAA; | |
TOP2A; | |
MET; CAMK2B; GSK3B; CSNK2A1; AKT1; DAPK1; SYK; NEK2; FLT3; MYLK; SRC; IGF1R; PTK2; BRAF; AURKB; AURKA; FLT4; EPHB4; MAP3K8; TEK; PDGFRB; INSR; PLK4; CDK1; EGFR; ERBB2; PIM1; NUAK1; ALK; AXL; NEK6; KDR; PLK1; PKN1; | |
CA12; CA5B; CA3; CA14; CA7; CA1; CA9; CA13; CA4; CA6; CA2; CA5A; | |
NR1H4; NR1H3; | |
PPARA; PPARG; PPARD; | |
RORC; | |
ESR1; ESR2; | |
KDM4E; | |
MAOA; ALOX5; XDH; | |
F10; F2; | |
MMP13; MMP12; MMP3; MMP2; MMP9; | |
BACE1; | |
STAT6; HIF1A; NFKB1; TP53; | |
FUT7; | |
ABCC1; ABCG2; | |
SLC22A6; SLC6A4; | |
SMAD3; LMNA; FABP5; SERPINA6; MAPT; PMP22; HBB; THPO; APP; TTR; HSPA1A; | |
L3MBTL1; SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | PIK3CG | PI3-kinase p110-gamma subunit | P48736 | CHEMBL3267 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | AMY1A;AMY1B;AMY1C | Salivary alpha-amylase | P04745 | CHEMBL2478 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
Enzyme_unclassified | APOBEC3G | DNA dC->dU-editing enzyme APOBEC-3G | Q9HC16 | CHEMBL1741217 |
Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 1 group H | NR1H3 | LXR-alpha | Q13133 | CHEMBL2808 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | MYLK | Myosin light chain kinase, smooth muscle | Q15746 | CHEMBL2428 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | BRAF | Serine/threonine-protein kinase B-raf | P15056 | CHEMBL5145 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
Protein Kinase | FLT4 | Vascular endothelial growth factor receptor 3 | P35916 | CHEMBL1955 |
Protein Kinase | EPHB4 | Ephrin type-B receptor 4 | P54760 | CHEMBL5147 |
Protein Kinase | MAP3K8 | Mitogen-activated protein kinase kinase kinase 8 | P41279 | CHEMBL4899 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | PDGFRB | Platelet-derived growth factor receptor beta | P09619 | CHEMBL1913 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | PLK4 | Serine/threonine-protein kinase PLK4 | O00444 | CHEMBL3788 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | ERBB2 | Receptor protein-tyrosine kinase erbB-2 | P04626 | CHEMBL1824 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | PLK1 | Serine/threonine-protein kinase PLK1 | P53350 | CHEMBL3024 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
Protein Phosphatase | DUSP3 | Dual specificity protein phosphatase 3 | P51452 | CHEMBL2635 |
Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
Serine protease | F10 | Coagulation factor X | P00742 | CHEMBL244 |
Serine protease | F2 | Thrombin | P00734 | CHEMBL204 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
SLC superfamily of solute carriers | SLC6A4 | Serotonin transporter | P31645 | CHEMBL228 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | SERPINA6 | Corticosteroid binding globulin | P08185 | CHEMBL2421 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | PMP22 | Peripheral myelin protein 22 | Q01453 | CHEMBL1293298 |
Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.058E-12 | 1.970E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, HBB, NOX4 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 8.569E-12 | 1.255E-09 | AXL, EGFR, ERBB2, F10, INSR, MET, NOX4, PDGFRB, PIK3CG, PIK3R1, PTK2, SRC, TEK, THPO |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.304E-11 | 4.360E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.277E-10 | 2.680E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, HBB, MPO, NOX4, SRC |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.381E-10 | 2.772E-08 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, HBB, XDH |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.062E-09 | 1.123E-07 | CYP19A1, F2, NFKB1, NR1H3, NR1H4, PPARA, PPARD, PPARG, PTPN2, SMAD3, TEK |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.696E-09 | 1.694E-07 | AURKB, CA2, CA7, EGFR, F2, HIF1A, NEK2, NPSR1, NR1H3, NR1H4, PLA2G1B, SYK, TNKS, TNKS2 |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 2.736E-09 | 2.613E-07 | EGFR, ERBB2, INSR, KDR, SYK |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.047E-09 | 2.835E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 4.277E-09 | 3.864E-07 | AKT1, AURKA, AURKB, CAMK2B, CDK1, GSK3B, NEK6, PKN1, PLK1, SRC, SYK, TNKS |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 7.975E-09 | 7.003E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.465E-08 | 1.213E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.689E-08 | 1.377E-06 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4 |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.847E-08 | 1.500E-06 | AURKB, CA2, CA7, CD38, EGFR, F2, HIF1A, KDR, NEK2, NPSR1, NR1H3, NR1H4, PARP1, PLA2G1B, SRC, SYK, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.517E-08 | 3.475E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 5.682E-08 | 4.311E-06 | EGFR, IGF1R, INSR, KDR, PTK2, SRC, SYK |
CC | GO:0044464; cell part | GO:0005829; cytosol | 1.131E-07 | 8.126E-06 | ACP1, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, APOBEC3G, APP, AURKA, AURKB, BLM, BRAF, CA1, CA13, CA2, CA3, CA7, CAMK2B, CDC25B, CDK1, CSNK2A1, DUSP3, EPHB4, ERBB2, FABP5, FLT3, GFER, GLO1, GSK3B, HBB, HIF1A, HPGD, HSD17B1, HSPA1A, LMNA, MAP3K8, MAPT, MYLK, NEK2, NEK6, NFKB1, PIK3CG, PIK3R1, PIM1, PKN1, PLA2G1B, PLK1, PLK4, PPARG, PTK2, PTPN1, PTPN2, PYGL, SLC6A4, SMAD3, SMN1, SMN2, SRC, STAT6, SYK, TNKS, TNKS2, TP53, XDH |
BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 1.903E-07 | 1.324E-05 | ALOX12, APP, AXL, CD38, EGFR, ERBB2, F2, GPR35, GSK3B, HIF1A, LMNA, NFKB1, NR1H3, NR1H4, PIK3CG, PIK3R1, PMP22, PPARD, PPARG, PTK2, PTPN2, SLC6A4, SMAD3, TEK, TERT, XDH |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 1.966E-07 | 1.359E-05 | AKR1B1, AKT1, ALOX5, APEX1, AURKA, AURKB, BLM, CAMK2B, CDC25B, CDK1, CSNK2A1, DUSP3, ESR1, ESR2, FABP5, GSK3B, HIF1A, HPGD, HSPA1A, L3MBTL1, LMNA, NEK2, NEK6, NFKB1, NR1H3, NR1H4, NUAK1, PARP1, PIM1, PKN1, PLK1, POLB, PPARA, PPARD, PPARG, PTPN2, RECQL, RORC, SMAD3, SMN1, SMN2, SRC, STAT6, TERT, TNKS, TOP2A, TP53, USP2 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 2.689E-07 | 1.830E-05 | CYP3A4, ESR1, ESR2, HSD17B1, NR1H3, NR1H4, RORC, SERPINA6 |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 2.892E-07 | 1.944E-05 | ALOX15, APP, BRAF, EGFR, FLT4, KDR, NOX4, PDGFRB, SRC, TEK, THPO |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 4.109E-07 | 2.647E-05 | CYP1A1, PDGFRB, POLB, PPARG, TP53 |
BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 6.009E-07 | 3.686E-05 | ESR1, ESR2, NR1H3, NR1H4, PPARA, PPARD, PPARG, RORC, SRC |
BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 6.248E-07 | 3.811E-05 | F2, FLT3, KDR, PDGFRB, PPARD, PTK2, TEK |
BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 7.394E-07 | 4.411E-05 | DRD4, NR1H3, PPARA, PPARG, RORC, TOP2A, TP53, USP2 |
BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 8.278E-07 | 4.845E-05 | ESR1, ESR2, NR1H3, NR1H4, PIM1, PPARA, PPARD, PPARG, RORC, SRC |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.439E-06 | 8.014E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.966E-06 | 1.070E-04 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, PKN1, TNKS |
MF | Unclassified; | GO:0032403; protein complex binding | 2.107E-06 | 1.136E-04 | ACHE, APEX1, EGFR, FLT3, IGF1R, INSR, KDR, MMP12, MMP13, MMP9, PIK3R1, PLK1, PPARA, PTPN1, PTPN2, PTPRF, SLC6A4, SMAD3, SRC, SYK |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 2.285E-06 | 1.225E-04 | AXL, IGF1R, INSR, PDGFRB, PIK3R1 |
BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 2.725E-06 | 1.437E-04 | FLT3, PDGFRB, PTK2, SRC, TEK |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 3.228E-06 | 1.670E-04 | AKT1, HIF1A, INSR, NOX4, NR1H4, PIK3R1, PPARG, PTPN2, PYGL |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 3.399E-06 | 1.745E-04 | CDK1, ESR1, ESR2, NR1H3, NR1H4, PPARA, PPARD, PPARG, RORC |
BP | GO:0009987; cellular process | GO:0038084; vascular endothelial growth factor signaling pathway | 3.899E-06 | 1.965E-04 | FLT3, FLT4, KDR, PDGFRB |
MF | Unclassified; | GO:0004872; receptor activity | 3.975E-06 | 1.999E-04 | ALK, AXL, CXCR1, DRD4, EGFR, EPHB4, ERBB2, ESR1, ESR2, F2, FLT3, FLT4, GPBAR1, GPR35, HPGD, IGF1R, INSR, KDR, MET, NPSR1, NR1H3, NR1H4, PDGFRB, PPARA, PPARD, PPARG, PTPRF, RORC, TEK |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 4.098E-06 | 2.042E-04 | CYP1A1, CYP2C8, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004556; alpha-amylase activity | 4.098E-06 | 2.042E-04 | AMY1A, AMY1B, AMY1C |
MF | Unclassified; | GO:0103025; alpha-amylase activity (releasing maltohexaose) | 4.098E-06 | 2.042E-04 | AMY1A, AMY1B, AMY1C |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 5.169E-06 | 2.518E-04 | ALOX12, ALOX15, ALOX5, HPGD |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 6.238E-06 | 2.973E-04 | EGFR, ERBB2, FLT4, IGF1R, INSR, KDR, PDGFRB, TEK |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 6.376E-06 | 3.018E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 6.720E-06 | 3.154E-04 | AURKB, NEK2, TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 7.886E-06 | 3.630E-04 | ALOX15, ESR1, GSK3B, HSPA1A, MAPT, MET, MMP3, PARP1, SRC, TP53 |
BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 8.151E-06 | 3.682E-04 | NR1H3, PPARA, PPARG |
BP | GO:0009987; cellular process | GO:0060336; negative regulation of interferon-gamma-mediated signaling pathway | 8.151E-06 | 3.682E-04 | NR1H3, PPARG, PTPN2 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 8.151E-06 | 3.682E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 9.088E-06 | 4.022E-04 | APP, CDK1, EGFR, F2, PARP1, PIK3R1, SMAD3 |
MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 1.012E-05 | 4.441E-04 | EGFR, ERBB2, MET, PDGFRB, PIK3CG, PIK3R1 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.155E-05 | 4.930E-04 | ABCC1, CA2, CA4, CA9, EGFR, ERBB2, HPGD, SLC22A6, TEK |
BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 1.341E-05 | 5.648E-04 | AKT1, EGFR, HBB, INSR, SMAD3 |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.344E-05 | 5.651E-04 | AKT1, HIF1A, LMNA, PPARD, SRC, TERT, TP53 |
MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 1.419E-05 | 5.929E-04 | FLT3, FLT4, KDR |
MF | GO:0098772; molecular function regulator | GO:0030235; nitric-oxide synthase regulator activity | 1.419E-05 | 5.929E-04 | AKT1, EGFR, ESR1 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.523E-05 | 6.329E-04 | HIF1A, MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.677E-05 | 6.888E-04 | AXL, FLT4, KDR, PIK3R1, PTK2, SRC |
BP | GO:0051179; localization | GO:0046326; positive regulation of glucose import | 1.702E-05 | 6.965E-04 | AKT1, INSR, NR1H4, PIK3R1, TERT |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 1.816E-05 | 7.362E-04 | MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 2.006E-05 | 8.015E-04 | HIF1A, SMAD3, TERT, TP53 |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 2.006E-05 | 8.015E-04 | HPGD, MMP2, MMP9, TERT |
MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 2.329E-05 | 9.172E-04 | AURKA, AXL, BRAF, EGFR, ERBB2, HIF1A, NFKB1, PIK3R1, PPARD, PPARG, SMAD3, TOP2A, TP53, TTR |
BP | GO:0009987; cellular process | GO:0070507; regulation of microtubule cytoskeleton organization | 2.711E-05 | 1.039E-03 | AURKA, GSK3B, HSPA1A, MAPT, MET, NEK2, PLK1, PLK4 |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 2.924E-05 | 1.113E-03 | ABCG2, ACHE, AKT1, APOBEC3G, BLM, CAMK2B, FLT3, FLT4, HPGD, MAPT, NFKB1, PYGL, SLC22A6, SLC6A4, SMAD3, TERT, TOP2A, XDH |
BP | GO:0050896; response to stimulus | GO:0046626; regulation of insulin receptor signaling pathway | 3.251E-05 | 1.219E-03 | NR1H4, PIK3R1, PTPN1, PTPN2, SRC |
BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 3.367E-05 | 1.251E-03 | APP, EGFR, MAPT |
BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 3.367E-05 | 1.251E-03 | BLM, RECQL, TP53 |
MF | GO:0005488; binding | GO:0032052; bile acid binding | 3.367E-05 | 1.251E-03 | NR1H4, PLA2G1B, PYGL |
BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 4.205E-05 | 1.521E-03 | CD38, CYP1A2, EGFR, ESR1, HPGD, PDGFRB, SLC6A4 |
BP | GO:0032501; multicellular organismal process | GO:0010595; positive regulation of endothelial cell migration | 4.333E-05 | 1.562E-03 | AKT1, FLT4, HIF1A, KDR, MET, TEK |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 4.629E-05 | 1.652E-03 | HIF1A, MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 4.674E-05 | 1.655E-03 | PARP1, SRC, TNKS, TNKS2 |
BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 4.674E-05 | 1.655E-03 | APP, GSK3B, IGF1R, PARP1 |
BP | GO:0008152; metabolic process | GO:0051974; negative regulation of telomerase activity | 4.784E-05 | 1.680E-03 | PPARG, SRC, TP53 |
CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 4.777E-05 | 1.680E-03 | AURKA, AURKB, CDK1, PLK1, POLB |
BP | GO:0008152; metabolic process | GO:0016572; histone phosphorylation | 5.422E-05 | 1.865E-03 | AURKA, AURKB, CDK1, PKN1 |
MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 5.422E-05 | 1.865E-03 | AKT1, MAPT, PTPN1, TP53 |
BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 5.588E-05 | 1.904E-03 | AKT1, AURKA, AURKB, BLM, CSNK2A1, L3MBTL1, NUAK1, TP53 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 5.597E-05 | 1.904E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 5.597E-05 | 1.904E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 5.597E-05 | 1.904E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 5.597E-05 | 1.904E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 5.721E-05 | 1.928E-03 | CDK1, EGFR, IGF1R, INSR, PLA2G1B |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 6.541E-05 | 2.178E-03 | IGF1R, INSR, PIK3R1 |
CC | GO:0016020; membrane | GO:0045121; membrane raft | 7.528E-05 | 2.454E-03 | APP, BACE1, EGFR, INSR, KDR, SLC22A6, SLC6A4, SRC, STAT6, TEK |
BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 7.992E-05 | 2.586E-03 | APP, CYP1B1, ERBB2, HSPA1A, LMNA, NOX4, PKN1, PMP22, PPARD, PPARG, PTPN2, SLC6A4, SMAD3, TERT, TP53, XDH |
BP | GO:0009987; cellular process | GO:0051983; regulation of chromosome segregation | 8.097E-05 | 2.608E-03 | AURKB, CSNK2A1, NEK2, NEK6, PLK1, TNKS |
BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 8.097E-05 | 2.608E-03 | AKT1, HIF1A, HSPA1A, MMP9, PTPN1, SRC |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 8.187E-05 | 2.619E-03 | AKT1, CYP1A2, EGFR, MMP9 |
CC | GO:0043226; organelle | GO:0051233; spindle midzone | 8.187E-05 | 2.619E-03 | APP, AURKA, AURKB, PLK1 |
BP | GO:0032501; multicellular organismal process | GO:0003007; heart morphogenesis | 9.303E-05 | 2.936E-03 | EPHB4, GAA, INSR, PTK2 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 9.303E-05 | 2.936E-03 | CSNK2A1, HIF1A, KDR, MAPT |
BP | GO:0065007; biological regulation | GO:0051091; positive regulation of DNA binding transcription factor activity | 9.352E-05 | 2.947E-03 | AKT1, ALK, APP, ESR1, ESR2, HSPA1A, NFKB1, PLA2G1B, PPARG |
BP | GO:0008152; metabolic process | GO:0035335; peptidyl-tyrosine dephosphorylation | 1.019E-04 | 3.178E-03 | ACP1, CDC25B, DUSP3, PTPN1, PTPN2, PTPRF |
BP | GO:0008152; metabolic process | GO:0046854; phosphatidylinositol phosphorylation | 1.019E-04 | 3.178E-03 | EGFR, ERBB2, MET, PDGFRB, PIK3CG, PIK3R1 |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 1.121E-04 | 3.459E-03 | CYP19A1, HSD17B1, HSD17B2 |
BP | GO:0009987; cellular process | GO:0010745; negative regulation of macrophage derived foam cell differentiation | 1.121E-04 | 3.459E-03 | NR1H3, PPARA, PPARG |
BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 1.186E-04 | 3.616E-03 | AURKB, NEK2, TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:0010389; regulation of G2/M transition of mitotic cell cycle | 1.272E-04 | 3.819E-03 | APP, AURKA, AURKB, BLM, CDK1, NEK2, PLK1, PLK4 |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 1.279E-04 | 3.831E-03 | MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0032502; developmental process | GO:0045597; positive regulation of cell differentiation | 1.388E-04 | 4.136E-03 | AKT1, APP, AURKA, AXL, BRAF, CA2, CAMK2B, HIF1A, KDR, MAPT, NFKB1, PARP1, PPARD, PPARG, SMAD3, SYK, TERT, THPO |
BP | GO:0032502; developmental process | GO:0060065; uterus development | 1.419E-04 | 4.211E-03 | CYP19A1, ESR1, SRC |
BP | GO:0051179; localization | GO:0015908; fatty acid transport | 1.478E-04 | 4.357E-03 | DRD4, PLA2G1B, PPARA, PPARD, PPARG |
BP | GO:0040011; locomotion | GO:0014911; positive regulation of smooth muscle cell migration | 1.489E-04 | 4.357E-03 | NOX4, PDGFRB, SRC, TERT |
CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 1.632E-04 | 4.732E-03 | ABCG2, APP, EGFR, ERBB2, FLT4, IGF1R, INSR, NR1H3, SMAD3, SYK |
MF | GO:0005488; binding | GO:0042826; histone deacetylase binding | 1.646E-04 | 4.767E-03 | HIF1A, HSPA1A, PARP1, PKN1, TOP2A, TP53 |
BP | GO:0050896; response to stimulus | GO:0034405; response to fluid shear stress | 1.660E-04 | 4.774E-03 | AKT1, CA2, PDGFRB, SRC |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.671E-04 | 4.774E-03 | CA2, CA7 |
BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 1.671E-04 | 4.774E-03 | GPBAR1, NR1H4 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.671E-04 | 4.774E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.671E-04 | 4.774E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.671E-04 | 4.774E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 1.671E-04 | 4.774E-03 | GPBAR1, NR1H4 |
BP | GO:0051179; localization | GO:0070198; protein localization to chromosome, telomeric region | 1.765E-04 | 5.016E-03 | TERT, TNKS, TNKS2 |
BP | GO:0032501; multicellular organismal process | GO:0045780; positive regulation of bone resorption | 1.765E-04 | 5.016E-03 | CA2, EGFR, SYK |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.784E-04 | 5.064E-03 | CA2, CA7, F2, KDR, NPSR1, PARP1, PLA2G1B, SRC |
MF | GO:0005488; binding | GO:0002039; p53 binding | 1.819E-04 | 5.150E-03 | BLM, GSK3B, HIF1A, NUAK1, TP53 |
BP | GO:0065007; biological regulation | GO:0060249; anatomical structure homeostasis | 1.902E-04 | 5.378E-03 | AKR1B1, APEX1, BLM, GAA, HIF1A, NOX4, PARP1, SRC, TERT |
BP | GO:0009987; cellular process | GO:0038128; ERBB2 signaling pathway | 2.043E-04 | 5.725E-03 | EGFR, ERBB2, PIK3R1, SRC |
BP | GO:0008152; metabolic process | GO:0032965; regulation of collagen biosynthetic process | 2.043E-04 | 5.725E-03 | F2, PDGFRB, PPARD, PPARG |
CC | GO:0044421; extracellular region part | GO:0070062; extracellular exosome | 2.093E-04 | 5.849E-03 | ABCC1, ACP1, AKR1B1, AKR1B10, ALDH1A1, ALK, ALOX12, AMY1A, AMY1B, AMY1C, APP, AXL, CA1, CA2, CA4, CA6, CD38, CDK1, DUSP3, EPHB4, F2, FABP5, GAA, GLO1, HBB, HPGD, HSPA1A, INSR, MMP9, MPO, MYLK, PDGFRB, PTPRF, PYGL, SERPINA6, SLC22A6, SRC, TTR |
BP | GO:0065007; biological regulation | GO:0051101; regulation of DNA binding | 2.108E-04 | 5.884E-03 | MMP9, NEK2, PARP1, PPARA, PPARG, TNKS |
BP | GO:0050896; response to stimulus | GO:0070920; regulation of production of small RNA involved in gene silencing by RNA | 2.160E-04 | 5.999E-03 | EGFR, ESR1, TERT |
BP | GO:0032501; multicellular organismal process | GO:0001503; ossification | 2.211E-04 | 6.119E-03 | ALOX15, EGFR, MMP13, MMP2, MMP9, TEK |
BP | GO:0050896; response to stimulus | GO:0043627; response to estrogen | 2.217E-04 | 6.126E-03 | CA2, ESR1, PDGFRB, PPARG, TEK |
BP | GO:0022610; biological adhesion | GO:0033628; regulation of cell adhesion mediated by integrin | 2.257E-04 | 6.220E-03 | CYP1B1, PIK3CG, PTK2, SYK |
BP | GO:0065007; biological regulation | GO:0051099; positive regulation of binding | 2.333E-04 | 6.390E-03 | APP, GSK3B, MET, MMP9, PARP1, PPARG, TERT |
BP | GO:0050896; response to stimulus | GO:0071214; cellular response to abiotic stimulus | 2.432E-04 | 6.595E-03 | AKT1, AURKB, BLM, EGFR, MYLK, NFKB1, NOX4, PIK3R1, TP53 |
BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 2.608E-04 | 6.994E-03 | CYP1A1, PPARD, PPARG |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 2.608E-04 | 6.994E-03 | CYP2C19, CYP2C8, CYP2C9 |
BP | GO:0050896; response to stimulus | GO:0071222; cellular response to lipopolysaccharide | 2.791E-04 | 7.447E-03 | AXL, NFKB1, NR1H3, NR1H4, PPARD, SRC |
BP | GO:0009987; cellular process | GO:0001961; positive regulation of cytokine-mediated signaling pathway | 2.995E-04 | 7.952E-03 | AXL, HIF1A, HSPA1A, MMP12 |
BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 3.002E-04 | 7.952E-03 | CDK1, ESR1, HIF1A, POLB, SMAD3, TNKS, TNKS2, TP53, USP2 |
CC | GO:0044422; organelle part | GO:0044432; endoplasmic reticulum part | 3.016E-04 | 7.980E-03 | APP, BACE1, CAMK2B, CDK1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, EGFR, F10, F2, FAAH, FLT3, HSD11B1, HSD17B2, NOX4, PIK3R1, PTPN1 |
BP | GO:0023052; signaling | GO:0050806; positive regulation of synaptic transmission | 3.053E-04 | 8.039E-03 | APP, BRAF, CA2, CA7, DRD4, EGFR |
BP | GO:0050896; response to stimulus | GO:0009416; response to light stimulus | 3.080E-04 | 8.100E-03 | AKT1, APP, AURKB, BRAF, EGFR, HIF1A, PIK3R1, TP53, USP2 |
BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 3.113E-04 | 8.166E-03 | AKT1, HIF1A, TERT |
BP | GO:0008152; metabolic process | GO:0032928; regulation of superoxide anion generation | 3.113E-04 | 8.166E-03 | EGFR, MAPT, SYK |
BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 3.209E-04 | 8.398E-03 | MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0009987; cellular process | GO:0007077; mitotic nuclear envelope disassembly | 3.275E-04 | 8.510E-03 | CDK1, LMNA, NEK6, PLK1 |
MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 3.275E-04 | 8.510E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 3.325E-04 | 8.548E-03 | EGFR, PLA2G1B |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 3.325E-04 | 8.548E-03 | TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 3.325E-04 | 8.548E-03 | PTPN1, PTPN2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.325E-04 | 8.548E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 3.325E-04 | 8.548E-03 | ESR1, ESR2 |
MF | GO:0005488; binding | GO:0051425; PTB domain binding | 3.325E-04 | 8.548E-03 | APP, INSR |
BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 3.574E-04 | 9.080E-03 | AKT1, LMNA, MMP9, TP53 |
BP | GO:0008152; metabolic process | GO:0032436; positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 3.604E-04 | 9.126E-03 | AKT1, AURKA, GSK3B, HSPA1A, PLK1 |
BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 3.604E-04 | 9.126E-03 | AKR1B1, AKT1, EGFR, PPARG, SRC |
BP | GO:0008152; metabolic process | GO:0050730; regulation of peptidyl-tyrosine phosphorylation | 3.623E-04 | 9.162E-03 | APP, EGFR, FLT3, PTPN1, PTPN2, SRC, SYK, TP53 |
BP | GO:0009987; cellular process | GO:0051259; protein oligomerization | 3.639E-04 | 9.171E-03 | ACHE, BLM, BRAF, HBB, HSD17B10, IGF1R, INSR, MAPT, SLC22A6, SLC6A4, TEK, TP53 |
CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 3.740E-04 | 9.383E-03 | ACHE, AKR1B1, APEX1, APP, AURKA, CA4, EGFR, ERBB2, HSPA1A, NOX4, PPARG, SRC, TNKS2, USP2 |
BP | Unclassified; | GO:0015758; glucose transport | 3.891E-04 | 9.651E-03 | AKT1, BRAF, PLA2G1B, PPARD |
BP | GO:0008152; metabolic process | GO:0042136; neurotransmitter biosynthetic process | 3.891E-04 | 9.651E-03 | ACHE, AKT1, CYP1B1, SLC6A4 |
MF | GO:0005488; binding | GO:0003682; chromatin binding | 4.054E-04 | 9.996E-03 | APEX1, CDK1, EGFR, ESR1, L3MBTL1, MPO, NFKB1, PKN1, PPARG, SMAD3, TOP2A, TP53 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.984E-24 | 2.795E-20 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.909E-18 | 3.574E-15 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, HBB |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.111E-15 | 4.321E-13 | APOBEC3G, BLM, CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, GLO1, L3MBTL1, MMP12, MMP13, MMP2, MMP3, MMP9, NR1H3, NR1H4, PARP1, PPARA, PPARD, PPARG, PTPN1, RORC, SMAD3, TNKS, TP53 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.485E-15 | 5.481E-13 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0005524; ATP binding | 3.449E-15 | 1.138E-12 | ABCC1, ABCG2, AKT1, ALK, AURKA, AURKB, AXL, BLM, BRAF, CAMK2B, CDK1, CSNK2A1, DAPK1, EGFR, EPHB4, ERBB2, FLT3, FLT4, GSK3B, HSPA1A, IGF1R, INSR, KDR, MAP3K8, MET, MYLK, NEK2, NEK6, NUAK1, PDGFRB, PIK3CG, PIM1, PKN1, PLK1, PLK4, PTK2, PYGL, RECQL, SRC, SYK, TEK, TOP2A, TP53 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 7.953E-23 | 1.567E-20 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.232E-13 | 1.214E-11 | CAMK2B; SRC; MMP2; BRAF; PIK3R1; HIF1A; ESR1; MMP9; PTK2; EGFR; PIK3CG; IGF1R; ERBB2; KDR; AKT1; TP53; MET |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.166E-12 | 7.654E-11 | PDGFRB; GSK3B; SMAD3; FLT3; DAPK1; MMP2; BRAF; PIK3R1; HIF1A; MMP9; EGFR; NFKB1; PIK3CG; PTK2; IGF1R; ERBB2; AKT1; PPARG; MET; TP53; PPARD |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 5.605E-12 | 2.760E-10 | PTPN1; SMAD3; CSNK2A1; SRC; INSR; ERBB2; ACP1; MET; PTPRF; EGFR; IGF1R |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 2.072E-11 | 8.165E-10 | PDGFRB; GSK3B; SRC; FLT4; BRAF; PIK3R1; PTK2; EGFR; PIK3CG; MYLK; IGF1R; ERBB2; KDR; AKT1; MET |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 4.464E-11 | 1.439E-09 | PDGFRB; GSK3B; ERBB2; AKT1; BRAF; PIK3R1; TP53; EGFR; NFKB1; PIK3CG; IGF1R |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 5.112E-11 | 1.439E-09 | PDGFRB; FLT3; ERBB2; AKT1; PIK3R1; TP53; MET; HIF1A; EGFR; PIK3CG |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 4.754E-10 | 8.785E-09 | PDGFRB; GSK3B; SYK; INSR; FLT4; PIK3R1; PTK2; EGFR; NFKB1; PIK3CG; IGF1R; KDR; AKT1; TEK; PKN1; TP53; MET |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.237E-10 | 5.508E-09 | CAMK2B; INSR; ERBB2; AKT1; TEK; PIK3R1; HIF1A; EGFR; NFKB1; PIK3CG; IGF1R |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 4.147E-10 | 8.785E-09 | PTPN1; GSK3B; INSR; AKT1; NR1H3; PIK3R1; PYGL; PPARA; NFKB1; PTPRF; PIK3CG |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 9.755E-10 | 1.478E-08 | PDGFRB; CAMK2B; AKT1; BRAF; PIK3R1; TP53; EGFR; PIK3CG; IGF1R |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 7.291E-10 | 1.197E-08 | CAMK2B; GSK3B; SRC; ERBB2; AKT1; BRAF; PIK3R1; EGFR; PTK2; PIK3CG |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.123E-09 | 1.580E-08 | SMAD3; ERBB2; AKT1; BRAF; PIK3R1; TP53; EGFR; NFKB1; PIK3CG |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.905E-10 | 8.785E-09 | DAPK1; SRC; MMP2; ERBB2; BRAF; MMP9; TP53; EGFR |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.191E-09 | 2.697E-08 | PDGFRB; AKT1; BRAF; PIK3R1; TP53; MET; EGFR; PIK3CG; IGF1R |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.637E-09 | 2.886E-08 | SRC; MMP2; AKT1; PIK3R1; ESR1; MMP9; EGFR; ESR2; PIK3CG; HSPA1A |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 4.714E-09 | 4.643E-08 | PDGFRB; SRC; INSR; FLT4; BRAF; PIK3R1; EGFR; PIK3CG; IGF1R; KDR; AKT1; TEK; MET |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.135E-08 | 8.943E-08 | PDGFRB; PLA2G1B; INSR; FLT4; PIK3R1; EGFR; NFKB1; PIK3CG; IGF1R; KDR; AKT1; TEK; MET |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.609E-09 | 2.886E-08 | HSD17B1; ALOX5; INSR; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 3.613E-09 | 3.746E-08 | GSK3B; ERBB2; AKT1; BRAF; PIK3R1; TP53; EGFR; PIK3CG |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 8.843E-09 | 7.282E-08 | CYP2C9; APP; CYP2C8; MAOA; ALOX5; ALOX15; BRAF; ALOX12; CYP2C19; SLC6A4 |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 6.655E-09 | 6.243E-08 | ALK; ERBB2; AKT1; BRAF; PIK3R1; TP53; EGFR; PIK3CG |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 7.694E-09 | 6.890E-08 | FLT3; PIM1; AKT1; BRAF; PIK3R1; NFKB1; PIK3CG; PPARD |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 4.633E-08 | 3.381E-07 | GSK3B; AKT1; NR1H3; BRAF; PIK3R1; PPARA; TP53; EGFR; NFKB1; PIK3CG |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 4.633E-08 | 3.381E-07 | PLK4; SMAD3; INSR; PLK1; AKT1; BRAF; PIK3R1; EGFR; PIK3CG; IGF1R |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.430E-07 | 1.544E-06 | PLA2G1B; MAOA; ALOX15; AKR1B1; ALOX12; PYGL; CYP2C19; CYP3A4; CYP19A1; HSD17B10; HSD11B1; FUT7; HSD17B1; ALOX5; HSD17B2; CD38; XDH; AMY1A; GAA; AMY1B; AMY1C; CYP2C9; CYP2C8; AKR1B10; CYP1A2; ALDH1A1; CYP1A1 |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 2.643E-07 | 1.627E-06 | GSK3B; SYK; CSNK2A1; CDK1; AKT1; CD38; PIK3R1; TP53; NFKB1; PIK3CG; HSPA1A |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 5.086E-08 | 3.578E-07 | GSK3B; SRC; AKT1; PIK3R1; ESR1; NFKB1; ESR2; PIK3CG |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 8.224E-08 | 5.587E-07 | HPGD; FLT3; MMP3; PPARG; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.243E-09 | 1.632E-08 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 8.871E-09 | 7.282E-08 | HSD11B1; HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 5.707E-07 | 3.123E-06 | PLK1; CDK1; AKT1; BRAF; PIK3R1; PIK3CG; CDC25B; IGF1R |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 4.137E-07 | 2.328E-06 | INSR; AKT1; PPARG; PIK3R1; TP53; NFKB1; PIK3CG; IGF1R |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.425E-07 | 9.357E-07 | HSD11B1; CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.200E-06 | 5.909E-06 | SMAD3; SRC; AKT1; STAT6; PIK3R1; TP53; MMP9; NFKB1; PIK3CG |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 7.944E-07 | 4.230E-06 | PTPN1; GSK3B; INSR; AKT1; BRAF; PIK3R1; PYGL; PTPRF; PIK3CG |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.623E-06 | 1.221E-05 | PDGFRB; DUSP3; AKT1; BRAF; MAP3K8; MAPT; TP53; EGFR; NFKB1; HSPA1A; CDC25B |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 3.208E-07 | 1.859E-06 | GSK3B; SMAD3; AKT1; BRAF; PIK3R1; TP53; PIK3CG |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.349E-06 | 1.129E-05 | GSK3B; SRC; AKT1; PIK3R1; TP53; ESR1; HIF1A; PIK3CG |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 2.665E-06 | 1.221E-05 | CAMK2B; GSK3B; AKT1; BRAF; PIK3R1; TP53; NFKB1; PIK3CG |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 9.946E-07 | 5.024E-06 | SMAD3; AKT1; BRAF; PIK3R1; TP53; NFKB1; PIK3CG |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.208E-07 | 1.859E-06 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 6.773E-06 | 2.965E-05 | GSK3B; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1; PIK3CG; HSPA1A |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 8.868E-06 | 3.565E-05 | SMAD3; MMP2; PIM1; AKT1; PIK3R1; NFKB1; PIK3CG |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 9.159E-06 | 3.609E-05 | GSK3B; CXCR1; SRC; AKT1; BRAF; PIK3R1; NFKB1; PTK2; PIK3CG |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.118E-05 | 4.155E-05 | PDGFRB; ABCC1; ERBB2; PIM1; CYP1B1; TP53; MMP9; MET; EGFR; NFKB1; CDC25B |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.031E-05 | 3.984E-05 | PDGFRB; SYK; CXCR1; INSR; AKT1; PIK3R1; EGFR; PIK3CG |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.458E-05 | 5.257E-05 | GSK3B; INSR; AKT1; NR1H3; PIK3R1; PPARA; NFKB1; PIK3CG |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.922E-05 | 6.529E-05 | PDGFRB; POLB; GSK3B; SMAD3; TERT; AKT1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 2.680E-05 | 8.949E-05 | PDGFRB; SRC; BRAF; PIK3R1; F2; PTK2; EGFR; PIK3CG; MYLK |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.554E-05 | 5.371E-05 | MMP3; AKT1; MAP3K8; PIK3R1; MMP9; NFKB1; PIK3CG |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 5.235E-06 | 2.344E-05 | SRC; KDR; AKT1; PIK3R1; PTK2; PIK3CG |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 7.323E-05 | 2.316E-04 | PARP1; LMNA; AKT1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 6.943E-06 | 2.974E-05 | INSR; AKT1; PIK3R1; PIK3CG; HSPA1A; IGF1R |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.275E-04 | 3.807E-04 | POLB; SYK; SRC; CDK1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 8.315E-06 | 3.413E-05 | AKT1; BRAF; PIK3R1; MET; HIF1A; PIK3CG |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.494E-05 | 5.257E-05 | GSK3B; SYK; AKT1; PIK3R1; NFKB1; PIK3CG |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 7.604E-06 | 3.187E-05 | CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.560E-04 | 4.390E-04 | CAMK2B; SRC; CD38; PIK3R1; EGFR; PIK3CG; MYLK |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.560E-04 | 4.390E-04 | THPO; PIM1; AKT1; STAT6; PIK3R1; PTPN2; PIK3CG |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 9.422E-05 | 2.900E-04 | PDGFRB; AKT1; PIK3R1; HIF1A; EGFR; PIK3CG |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.108E-04 | 3.359E-04 | GSK3B; AKT1; MAP3K8; PIK3R1; NFKB1; PIK3CG |
hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 8.446E-07 | 4.379E-06 | AMY1A; AMY1B; AMY1C; AKT1; PIK3R1; PIK3CG |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.078E-05 | 4.083E-05 | CYP2C9; CYP2C8; MAOA; CYP1A2; CYP3A4; CYP2C19 |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 3.821E-05 | 1.254E-04 | AKT1; PIK3R1; TP53; NFKB1; PTK2; PIK3CG |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 6.148E-04 | 1.477E-03 | SMAD3; CXCR1; SRC; KDR; MET; EGFR; HSPA1A; IGF1R |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.494E-05 | 5.257E-05 | HSD11B1; CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 2.654E-04 | 6.971E-04 | SYK; SRC; AKT1; PIK3R1; PIK3CG; MYLK |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 2.215E-04 | 6.061E-04 | ALOX5; AKT1; PIK3R1; NFKB1; PIK3CG; HSPA1A |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.427E-04 | 6.549E-04 | ABCC1; AKT1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 7.139E-04 | 1.674E-03 | PDGFRB; CXCR1; THPO; FLT3; FLT4; KDR; MET; EGFR |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 5.969E-04 | 1.452E-03 | CAMK2B; GSK3B; SMAD3; CSNK2A1; TP53; PPARD |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 4.052E-04 | 1.023E-03 | SYK; AKT1; PPARG; PIK3R1; NFKB1; PIK3CG |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 2.897E-04 | 7.413E-04 | INSR; AKT1; PPARG; PIK3R1; PIK3CG; IGF1R |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 5.969E-04 | 1.452E-03 | GSK3B; SMAD3; AKT1; PIK3R1; PIK3CG; IGF1R |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 6.309E-04 | 1.497E-03 | CAMK2B; AKT1; BRAF; PIK3R1; PPARA; NFKB1; PIK3CG |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 2.897E-04 | 7.413E-04 | GSK3B; SMAD3; PLK1; CDK1; TP53; CDC25B |
hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 2.025E-03 | 4.051E-03 | PDGFRB; CAMK2B; ERBB2; CD38; EGFR; MYLK |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.757E-03 | 3.590E-03 | GSK3B; AKT1; PIK3R1; NFKB1; PIK3CG; HSPA1A |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.053E-03 | 2.357E-03 | AKT1; MAP3K8; PIK3R1; NFKB1; PIK3CG |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.294E-03 | 2.801E-03 | CAMK2B; ACHE; AKT1; PIK3R1; PIK3CG |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 7.390E-04 | 1.693E-03 | CAMK2B; SRC; ALOX12; PIK3R1; PIK3CG |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 9.667E-04 | 2.189E-03 | SMAD3; AKT1; PIK3R1; NFKB1; PIK3CG |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 7.407E-05 | 2.316E-04 | AKT1; BRAF; PIK3R1; HIF1A; PIK3CG |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 2.579E-04 | 6.866E-04 | SRC; PIK3R1; MET; PTK2; PIK3CG |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 2.280E-02 | 3.775E-02 | CAMK2B; AKT1; PIK3R1; PIK3CG |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 9.673E-03 | 1.701E-02 | CAMK2B; SYK; SRC; AKT1; NFKB1 |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 1.697E-03 | 3.555E-03 | MMP2; PIK3R1; MMP9; PTK2; PIK3CG |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 7.459E-03 | 1.336E-02 | INSR; AKT1; PIK3R1; PIK3CG; MYLK |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 1.350E-04 | 3.968E-04 | CXCR1; SRC; MET; EGFR; NFKB1 |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 2.036E-03 | 4.051E-03 | CAMK2B; PLK1; CDK1; AURKA; IGF1R |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 7.644E-03 | 1.357E-02 | BACE1; APP; GSK3B; MAPT; HSD17B10 |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 2.505E-03 | 4.935E-03 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 1.689E-02 | 2.843E-02 | SYK; BRAF; PIK3R1; PIK3CG |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 1.378E-02 | 2.382E-02 | GSK3B; MET; PTK2; EPHB4 |
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.447E-04 | 4.191E-04 | FABP5; NR1H3; PPARG; PPARA; PPARD |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 6.286E-03 | 1.136E-02 | CAMK2B; AKT1; PYGL; PPARA |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 6.071E-03 | 1.107E-02 | PIK3R1; NFKB1; PTK2; PIK3CG |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 4.350E-03 | 8.239E-03 | CAMK2B; SRC; MMP2; EGFR |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 4.699E-03 | 8.733E-03 | SYK; AKT1; PIK3R1; PIK3CG |
hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 5.303E-05 | 1.712E-04 | AMY1A; AMY1B; GAA; AMY1C; PYGL |
hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 2.618E-02 | 4.298E-02 | THPO; FLT3; CD38 |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 4.699E-03 | 8.733E-03 | SYK; CSNK2A1; PARP1; NFKB1 |
hsa04970 | Salivary secretion_Homo sapiens_hsa04970 | 4.018E-03 | 7.685E-03 | AMY1A; AMY1B; AMY1C; CD38 |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 3.859E-03 | 7.453E-03 | PDGFRB; SRC; CDK1; EGFR |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.506E-03 | 3.191E-03 | SYK; AKT1; PIK3R1; PIK3CG |
hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 1.663E-02 | 2.825E-02 | CAMK2B; CA2; MYLK |
hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.434E-02 | 2.457E-02 | AKT1; PPARA; NFKB1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.768E-03 | 3.590E-03 | CA2; NR1H4; CYP3A4; ABCG2 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 7.266E-04 | 1.684E-03 | INSR; AKT1; PIK3R1; PIK3CG |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 1.274E-03 | 2.788E-03 | SMAD3; RORC; STAT6; NFKB1 |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 5.086E-03 | 9.364E-03 | INSR; PIK3R1; PIK3CG |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.978E-04 | 5.487E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 2.818E-03 | 5.496E-03 | INSR; PIK3R1; PIK3CG |
hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.800E-02 | 4.558E-02 | AKR1B10; AKR1B1 |
hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 2.246E-02 | 3.750E-02 | AKR1B10; AKR1B1 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.188E-03 | 2.629E-03 | BRAF; PPARG; TP53 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.313E-03 | 2.811E-03 | AKR1B10; GAA; AKR1B1 |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.736E-03 | 3.590E-03 | POLB; PARP1; APEX1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.195E-02 | 2.084E-02 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 5.146E-04 | 1.283E-03 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; PIK3CG; PIK3CG; AURKA; PLK1 |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
NA: NA | Haemophilia B | NA | F10 |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F10; F2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; FAAH; CYP3A4 |
NA: NA | Angioedema | NA | PIK3CG |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | SLC6A4 |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
NA: NA | Postmenopausal disorder | NA | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT; EGFR; EGFR; EGFR; TP53; KDR; KDR |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
I00-I99: Diseases of the circulatory system | Heart arrhythmia | I47-I49 | F2 |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
NA: NA | Chemotherapyinduced emesis | NA | SLC6A4 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
I00-I99: Diseases of the circulatory system | Thromboembolic disorders | I80-I82 | F10 |
I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F10; F2 |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F10; ALOX5; SYK; F2; F2 |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Thrombocytopenia | D69.6, P61.0 | F2 |
C00-D49: Neoplasms | Thyroid cancer | C73 | BRAF; KDR |
I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | F10 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; EGFR; EGFR; ERBB2; TP53; KDR |
NA: NA | Colour dead tissues | NA | PTPN1 |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; FLT3; FLT3; AURKB; AURKA; TP53; TP53; PLK1 |
I00-I99: Diseases of the circulatory system | Stroke in atrial fibrillation | I48, I61-I63 | F2 |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; EGFR |
NA: NA | Chronic low back pain | NA | SLC6A4 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | SLC6A4; ERBB2 |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | SLC6A4; SLC6A4 |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR; ERBB2; KDR; KDR |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
H00-H59: Diseases of the eye and adnexa | Retinal venous occlusion | H34.8 | ERBB2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | F10; EGFR; PARP1 |
I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; PPARD |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | PDGFRB; APP |
G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
NA: NA | Christmas disease | NA | F10 |
NA: NA | Menopausal staging | NA | SLC6A4 |
NA: NA | Menopausal disorder | NA | ESR1 |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
C00-D49: Neoplasms | Melanoma | C43 | TERT; BRAF; EGFR; PARP1; KDR; KDR |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; MMP12; MMP12 |
C00-D49: Neoplasms | Renal cancer | C64 | F10; CA9; KDR |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
C00-D49: Neoplasms | Cancer | C00-C96 | MET; GSK3B; CSNK2A1; AKT1; SYK; PIK3CG; CA1; FLT3; FLT3; CA9; SLC6A4; MMP2; F2; ACHE; SRC; IGF1R; PTK2; BRAF; BRAF; AURKA; FLT4; EPHB4; TEK; HIF1A; CDK1; MMP9; NFKB1; EGFR; ERBB2; ERBB2; PIM1; PARP1; CDC25B; CD38; TP53; ESR1; ESR1; KDR; PLK1; APP |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F10; F2 |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; SLC6A4; SLC6A4; FAAH |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | PIK3CG; F2; KDR |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; KDR |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; EGFR; ERBB2 |
I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F10; F2 |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
C00-D49: Neoplasms | Breast cancer | C50 | TERT; CYP19A1; PIK3CG; FLT3; FLT3; CA9; IGF1R; INSR; CDK1; EGFR; EGFR; EGFR; ERBB2; ERBB2; ERBB2; ESR1; ESR1; KDR; KDR; KDR |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | PIK3CG; KDR |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; GPBAR1 |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | PIK3CG; CYP2C9 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F10; F2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; F2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; INSR; ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | F10; SLC6A4 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; EGFR |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
C00-D49: Neoplasms | Prostate cancer | C61 | TERT; PIK3CG; FLT3; FLT4; EGFR; ERBB2; ESR1; PLK1 |
I00-I99: Diseases of the circulatory system | Prophylaxis of deep vein thrombosis | I80-I82, I80.2 | F10 |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; ESR1 |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood forming organ disorders | D75.9 | F2 |
C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; SRC; EGFR; EGFR; ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depression | F32, F33 | SLC6A4 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | F2; NPSR1; ESR1; APP |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; SLC6A4; SLC6A4 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; TEK |
C00-D49: Neoplasms | Solid tumors | NA | BRAF |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5; PIK3CG; TEK |
J00-J99: Diseases of the respiratory system | Asthma | J45 | SERPINA6; PLA2G1B; ALOX5; ALOX5; SYK; SYK; MMP12; ERBB2 |
NA: NA | Appetite suppressant | NA | SLC6A4 |
G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; ALOX5; MMP12; PPARD |
C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; PPARG; PPARD |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; PTPN1; PTPN1; PIK3CG; PIK3CG; INSR; NFKB1; PPARG; PPARG; GPBAR1; PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Smoking cessation | F17.2 | SLC6A4 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AKT1; SYK; PIK3CG; FLT3; CA9; MMP2; F2; SRC; IGF1R; PTK2; AURKB; AURKA; FLT4; TEK; PDGFRB; HIF1A; MMP9; EGFR; ERBB2; TP53; KDR; KDR; KDR; PLK1; PLK1; TOP2A |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; PTPN1; SLC6A4; PPARG; PPARD; PPARD |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK; PIK3CG; PIK3CG; ERBB2; PLK1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; INSR |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
NA: NA | Nonvalvular atrial fibrillation | NA | F2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; SERPINA6; PLA2G1B; ALOX5; MMP13; SYK; PIK3CG; MMP12; SLC6A4; FAAH |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
NA: NA | Upper abdominal bloating | NA | ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
NA: NA | Enthesopathy | NA | PIK3CG |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TEK; KDR |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; PIK3CG; PIK3CG; CA9; INSR; HIF1A; EGFR; ERBB2; PLK1 |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; FAAH |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; FLT4; EGFR |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F10; F2 |
I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F10; F2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vascular restinosis following vascular graft surgery | T82.858A | FLT4 |
N00-N99: Diseases of the genitourinary system | Vasomotor symptoms | N95.1 | SLC6A4 |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
C00-D49: Neoplasms | Endometrial cancer | C54.1 | PIK3CG; PIK3CG |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG |
I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F10; F2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | SLC6A4; DRD4 |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; F2; ESR1; ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PIK3CG; MMP3; F2; F2; PARP1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; PPARD |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; IGF1R; IGF1R; PDGFRB; EGFR; EGFR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
C00-D49: Neoplasms | Liver cancer | C22 | TERT; IGF1R; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
C00-D49: Neoplasms | Late-stage non-small cell lung cancer | C33-C34 | EPHB4 |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; ESR1 |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; BRAF; AURKA; TP53 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
NA: NA | Dyslipidemia | NA | PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2; MYLK |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ALOX5; SYK; MMP3 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B; SRC |
C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; MMP2; EGFR; EGFR; PARP1; KDR; KDR; KDR; KDR |
NA: NA | Edema | NA | CA2 |
J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; FLT4; KDR |
C00-D49: Neoplasms | HER2-positive urogenital cancer | NA | ERBB2 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hemophilia | D66-D68 | F10 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; SRC; AURKB; CD38; TP53 |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hematology | D50-D77 | F10 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1; PIK3CG |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
C00-D49: Neoplasms | Diffuse large B-cell lymphoma | C83.3 | PIK3CG |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT; AKT1; FLT3; MMP2; EGFR; KDR; PLK1 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MMP13; SLC6A4; ACHE; IGF1R; INSR; CDK1; FAAH; ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; SLC6A4; ACHE; BRAF |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic macular edema | E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35.8, R60.9 | SERPINA6 |
H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | SERPINA6 |
NA: NA | Obstructive airway diseases | NA | SERPINA6 |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; CA4; CA4 |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; HSD11B1; AKR1B1; GSK3B; PTPN1; PDGFRB; INSR; PPARG |
I00-I99: Diseases of the circulatory system | Deep venous clots | I80.2 | F10 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; SLC6A4; SLC6A4; SLC6A4 |
NA: NA | Depressive disorders | NA | SLC6A4 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; ESR1; ESR1 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; SYK |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP2; MMP3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; PPARD; ESR1 |
I00-I99: Diseases of the circulatory system | Deep vein thrombosis | I80-I82, I80.2 | F10 |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | SLC6A4 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
C00-D49: Neoplasms | Metastatic melanoma | C43 | BRAF; BRAF |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
NA: NA | Myalgia | NA | SLC6A4 |
C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; SRC; IGF1R; CD38 |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | ERBB2; KDR |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; GSK3B; MAPT; ACHE; ACHE; ACHE; INSR; PPARG; PPARG; APP |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; EGFR; EGFR; ERBB2 |
C00-D49: Neoplasms | Glioma | C71 | PIK3CG; EGFR; EGFR; KDR; APP |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; SLC6A4 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH; PPARG |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
NA: NA | Geographic retinal atrophy | NA | APP |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE |
NA: NA | GIST | NA | FLT3 |